ABSTRACT
Frontotemporal lobar degeneration (FTLD) is a progressive neurodegenerative syndrome. Defects of copper (Cu) and iron (Fe) homeostasis are involved in the development of several neurodegenerative diseases and their homeostasis is interconnected by the Cu-protein ceruloplasmin (Cp), responsible for Fe oxidative state. In this study we assessed Fe, transferrin (Trf), ferritin, Cp specific activity (eCp/iCp), Cp/Trf ratio, and Trf saturation in 60 FTLD patients and 43 healthy controls, and discussed the results in relation to Cu homeostasis. The significant decrease of the eCp/iCp in the FTLD patients supports the involvement of Fe imbalance in the onset and progression of FTLD.
Subject(s)
Ceruloplasmin/metabolism , Ferritins/blood , Frontotemporal Lobar Degeneration/blood , Iron/blood , Transferrin/metabolism , Aged , Aphasia, Primary Progressive/blood , Aphasia, Primary Progressive/metabolism , Case-Control Studies , Female , Frontotemporal Dementia/blood , Frontotemporal Dementia/metabolism , Humans , Iron/metabolism , Male , Middle AgedABSTRACT
BACKGROUND: Primary progressive aphasia (PPA) is a heterogeneous syndrome that is difficult to diagnose at early stages. Plasma neurofilament light chain (NFL) has been proposed as a potential biomarker for PPA. OBJECTIVE: To examine the diagnostic properties of plasma NFL in PPA and to evaluate its association with clinical stages of the disease and brain metabolism. METHODS: Our study included 80 participants (13 with non-fluent, 12 with semantic, and 16 with logopenic variant PPA; 13 with amnestic Alzheimer's disease [AD]; 13 with behavioral variant frontotemporal dementia; and 13 healthy controls). Plasma NFL concentration was measured using a high-sensitivity enzyme-linked immunosorbent assay (ELISA) kit. PET imaging was performed in a subgroup of patients. RESULTS: NFL discriminated patients from controls with an area under the curve of 0.914 (95% CI, 0.843-0.984; pâ<â0.001) (cut-off: 76.46 pg/mL; 94% sensitivity, 76.9% specificity). There were no significant differences between clinical syndromes (PPA subtypes), the main clinical forms of dementia (frontotemporal dementia and AD), or the expected pathological groups (frontotemporal lobar degeneration-tau [FTLD-tau], FTLD-TDP43, and AD). NFL levels showed weak to moderate correlations with age and functional scale score. We found no significant correlation with the extent of hypometabolism observed on FDG-PET images. CONCLUSION: Plasma NFL is a non-specific marker of neurodegeneration, and may be helpful in the diagnosis of PPA. However, NFL does not permit differential diagnosis between PPA subtypes and is not correlated with the extent of neurodegeneration.
Subject(s)
Aphasia, Primary Progressive/blood , Aphasia, Primary Progressive/diagnostic imaging , Neurofilament Proteins/blood , Aged , Aged, 80 and over , Biomarkers/blood , Cross-Sectional Studies , Female , Humans , Male , Middle AgedABSTRACT
Progranulin is a multifunctional growth factor mainly expressed in neurons and microglia. Loss-of-function mutations in the Granulin (GRN) gene are causative of frontotemporal dementia with TAR DNA-binding protein-43 inclusions. We reported the case of a 51-year-old male patient affected by sporadic agrammatic variant of primary progressive aphasia, in whom we identified a novel heterozygous deletion in the exon 6 (g.10338_39delAG, p.Arg161GlyfsX36). Plasma progranulin levels were significantly reduced and in silico analysis predicted a premature termination codon. This case expands our knowledge on GRN mutations in frontotemporal dementia.
Subject(s)
Aphasia, Primary Progressive/genetics , Frontotemporal Dementia/genetics , Intercellular Signaling Peptides and Proteins/genetics , Mutation , Aphasia, Primary Progressive/blood , Aphasia, Primary Progressive/cerebrospinal fluid , Aphasia, Primary Progressive/diagnostic imaging , Brain/diagnostic imaging , Frontotemporal Dementia/blood , Frontotemporal Dementia/cerebrospinal fluid , Frontotemporal Dementia/diagnostic imaging , Heterozygote , Humans , Intercellular Signaling Peptides and Proteins/blood , Male , Middle Aged , ProgranulinsABSTRACT
OBJECTIVE: To assess the utility of serum neurofilament for diagnosis and monitoring of primary progressive aphasia (PPA) variants. METHODS: We investigated neurofilament light chain (NF-L) levels in blood of 99 patients with PPA (40 with nonfluent variant PPA [nfvPPA], 38 with semantic variant PPA [svPPA], 21 with logopenic variant PPA [lvPPA]) and compared diagnostic performance with that reached by CSF NF-L, phosphorylated neurofilament heavy chain (pNF-H), ß-amyloid (Aß1-42), tau, and phosphorylated tau. The longitudinal change of blood NF-L levels was measured and analyzed for correlation with functional decline and brain atrophy. RESULTS: Serum NF-L is increased in PPA compared to controls and discriminates between nfvPPA/svPPA and lvPPA with 81% sensitivity and 67% specificity (cutoff 31 pg/mL). CSF NF-L, pNF-H, tau, phosphorylated tau, and Aß1-42 achieved similar performance, and pNF-H was the only marker for discrimination of nfvPPA from svPPA/lvPPA. In most patients with nfvPPA and svPPA, but not lvPPA, serum NF-L increased within follow-up. The increase correlated with functional decline and progression of atrophy of the left frontal lobe of all patients with PPAs and the right middle frontal gyrus of patients with nfvPPA and svPPA. CONCLUSIONS: Blood level of NF-L can aid the differential diagnosis of PPA variants, especially in combination with CSF pNF-H. Because serum NF-L correlates with functional decline and atrophy in the disease course, it qualifies as an objective disease status marker. Extended follow-up studies with cases of known neuropathology are imperative. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that in patients with PPA, blood levels of NF-L can distinguish the logopenic variant from the nonfluent/agrammatic and semantic variants.
Subject(s)
Aphasia, Primary Progressive/blood , Neurofilament Proteins/blood , Adult , Aged , Aged, 80 and over , Amyloid beta-Peptides/blood , Amyloid beta-Peptides/cerebrospinal fluid , Aphasia, Primary Progressive/diagnostic imaging , Atrophy/diagnostic imaging , Atrophy/pathology , Biomarkers , Brain/diagnostic imaging , Brain/pathology , Female , Humans , Longitudinal Studies , Magnetic Resonance Imaging , Male , Middle Aged , Neurofilament Proteins/cerebrospinal fluid , Peptide Fragments/blood , Peptide Fragments/cerebrospinal fluid , ROC Curve , tau Proteins/blood , tau Proteins/cerebrospinal fluidSubject(s)
Aphasia, Primary Progressive/genetics , Intercellular Signaling Peptides and Proteins/genetics , Mutation/genetics , Parkinsonian Disorders/genetics , Aged , Aphasia, Primary Progressive/blood , Aphasia, Primary Progressive/complications , Aphasia, Primary Progressive/diagnostic imaging , DNA Mutational Analysis , Family Health , Female , Humans , Intercellular Signaling Peptides and Proteins/blood , Magnetic Resonance Imaging , Parkinsonian Disorders/blood , Parkinsonian Disorders/complications , Parkinsonian Disorders/diagnostic imaging , ProgranulinsABSTRACT
OBJECTIVE: To investigate serum neurofilament light chain (NfL) concentrations in frontotemporal dementia (FTD) and to see whether they are associated with the severity of disease. METHODS: Serum samples were collected from 74 participants (34 with behavioral variant FTD [bvFTD], 3 with FTD and motor neuron disease and 37 with primary progressive aphasia [PPA]) and 28 healthy controls. Twenty-four of the FTD participants carried a pathogenic mutation in C9orf72 (9), microtubule-associated protein tau (MAPT; 11), or progranulin (GRN; 4). Serum NfL concentrations were determined with the NF-Light kit transferred onto the single-molecule array platform and compared between FTD and healthy controls and between the FTD clinical and genetic subtypes. We also assessed the relationship between NfL concentrations and measures of cognition and brain volume. RESULTS: Serum NfL concentrations were higher in patients with FTD overall (mean 77.9 pg/mL [SD 51.3 pg/mL]) than controls (19.6 pg/mL [SD 8.2 pg/mL]; p < 0.001). Concentrations were also significantly higher in bvFTD (57.8 pg/mL [SD 33.1 pg/mL]) and both the semantic and nonfluent variants of PPA (95.9 and 82.5 pg/mL [SD 33.0 and 33.8 pg/mL], respectively) compared with controls and in semantic variant PPA compared with logopenic variant PPA. Concentrations were significantly higher than controls in both the C9orf72 and MAPT subgroups (79.2 and 40.5 pg/mL [SD 48.2 and 20.9 pg/mL], respectively) with a trend to a higher level in the GRN subgroup (138.5 pg/mL [SD 103.3 pg/mL). However, there was variability within all groups. Serum concentrations correlated particularly with frontal lobe atrophy rate (r = 0.53, p = 0.003). CONCLUSIONS: Increased serum NfL concentrations are seen in FTD but show wide variability within each clinical and genetic group. Higher concentrations may reflect the intensity of the disease in FTD and are associated with more rapid atrophy of the frontal lobes.
Subject(s)
Frontotemporal Dementia/blood , Neurofilament Proteins/blood , Aged , Aphasia, Primary Progressive/blood , Aphasia, Primary Progressive/diagnostic imaging , Aphasia, Primary Progressive/genetics , Atrophy , Biomarkers/blood , C9orf72 Protein , Disease Progression , Female , Follow-Up Studies , Frontal Lobe/diagnostic imaging , Frontotemporal Dementia/diagnostic imaging , Frontotemporal Dementia/genetics , Humans , Intercellular Signaling Peptides and Proteins/genetics , Magnetic Resonance Imaging , Male , Middle Aged , Motor Neuron Disease/blood , Motor Neuron Disease/diagnostic imaging , Motor Neuron Disease/genetics , Progranulins , Proteins/genetics , Psychometrics , Severity of Illness Index , tau Proteins/geneticsABSTRACT
Mutations in progranulin gene (GRN) are a common cause of autosomal dominant frontotemporal lobar degeneration syndromes and are associated with a wide phenotypic heterogeneity. The majority of genetic defects in GRN consists of loss-of-function mutations, causing haploinsufficiency, and is associated with extremely low plasma progranulin levels. Herein, we describe a patient who developed language dysfunctions and memory disturbances at 63 years of age. Considering the early onset and the positive family history (sister aged 50 with non-fluent/agrammatic variant of primary progressive aphasia, father with behavioral disturbances in his sixties), a genetic analysis was carried out, showing the presence of a novel mutation [g.9543delA (IVS3-2delA)] in a predicted splicing site of GRN. Her progranulin plasma levels were under the reference threshold, as in her sister, thus supporting the causative role of the new variant. The same genetic mutation was confirmed by sequencing in her sister. Results described enlarge current knowledge on genetic causes of the disease and clinical characteristics of carriers.